
Junko Hamamoto

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4555877/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Functional dissection of the KRAS G12C mutation by comparison among multiple oncogenic driver mutations in a lung cancer cell line model. Biochemical and Biophysical Research Communications, 2021, 534, 1-7.	1.0	2
2	Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Research, 2021, 81, 3916-3929.	0.4	13
3	A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. Lung Cancer, 2021, 162, 140-146.	0.9	32
4	Intracellular levels of reactive oxygen species correlate with ABTâ€263 sensitivity in nonâ€smallâ€cell lung cancer cells. Cancer Science, 2020, 111, 3793-3801.	1.7	4
5	IGF2 Autocrine-Mediated IGF1R Activation Is a Clinically Relevant Mechanism of Osimertinib Resistance in Lung Cancer. Molecular Cancer Research, 2020, 18, 549-559.	1.5	34
6	Monomer Preference of EGFR Tyrosine Kinase Inhibitors Influences the Synergistic Efficacy of Combination Therapy with Cetuximab. Molecular Cancer Therapeutics, 2019, 18, 1593-1601.	1.9	4
7	Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare <i>ECFR</i> mutations. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 10025-10030.	3.3	41
8	Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations. Lung Cancer, 2019, 127, 146-152.	0.9	42
9	Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in <i>EGFR</i> -Mutated Non–Small Cell Lung Cancer. Molecular Cancer Therapeutics, 2018, 17, 740-750.	1.9	27
10	Amplification of EGFR Wild-Type Alleles in Non–Small Cell Lung Cancer Cells Confers Acquired Resistance to Mutation-Selective EGFR Tyrosine Kinase Inhibitors. Cancer Research, 2017, 77, 2078-2089.	0.4	126
11	Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer. Molecular Cancer Research, 2017, 15, 106-114.	1.5	54
12	Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in <i>ALK</i> -Translocated Lung Cancer Cells. Molecular Cancer Therapeutics, 2016, 15, 162-171.	1.9	54
13	Long-term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR-mutant PC9 lung cancer cell line. International Journal of Oncology, 2015, 46, 430-436.	1.4	12
14	Multiple roles of extracellular fibroblast growth factors in lung cancer cells. International Journal of Oncology, 2015, 46, 423-429.	1.4	15
15	Characterization of the cell of origin and propagation potential of the fibroblast growth factor 9-induced mouse model of lung adenocarcinoma. Journal of Pathology, 2015, 235, 593-605.	2.1	23
16	Methylationâ€induced downregulation of TFPI â€2 causes TMPRSS 4 overexpression and contributes to oncogenesis in a subset of nonâ€smallâ€cell lung carcinoma. Cancer Science, 2015, 106, 34-42.	1.7	18
17	<i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer. Oncotarget, 2015, 6, 38789-38803.	0.8	137
18	Claudin-1 is a novel target of miR-375 in non-small-cell lung cancer. Lung Cancer, 2014, 85, 366-372.	0.9	41

JUNKO ΗΑΜΑΜΟΤΟ

#	Article	IF	CITATIONS
19	Expression of fibroblast growth factor 9 is associated with poor prognosis in patients with resected non-small cell lung cancer. Lung Cancer, 2014, 83, 90-96.	0.9	44
20	Activation of the FGF2-FGFR1 Autocrine Pathway: A Novel Mechanism of Acquired Resistance to Gefitinib in NSCLC. Molecular Cancer Research, 2013, 11, 759-767.	1.5	179
21	Identification of microRNAs differentially expressed between lung squamous cell carcinoma and lung adenocarcinoma. Molecular Medicine Reports, 2013, 8, 456-462.	1.1	59